^
    Back
    Association details:
    Biomarker:HER-2 elevation + TMB-H
    Cancer:Gastric Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    1489P - Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen

    Published date:
    09/14/2020
    Excerpt:
    A 37-case GC cohort receiving immune checkpoint inhibitor (ICI) therapy was also cited for further analysis....In contrast, ERBB2-high-TMB-high patients displayed a better response to ICI therapy than ERBB2-high-TMB-low patients (ORR=50% vs 16.7%, DCR=75% vs 50%, mPFS=13.57 vs 2.53 month).